ACTA1 and scleroderma: Studies using scleroderma cells revealed that treatment with TGF‐β1, in combination with antibodies BB7 and a pan‐TGF‐β blocking antibody, or in the presence of an ALK5 inhibitor for 48 hours, resulted in a reduction of Col‐1, TNC, CCN2, and αSMA to levels comparable with control cells (Figure 4A).